Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0356 | Idebenone

Molecular Formula C19H30O5
Molecular Weight 338.4
Structure
State solid
Volume of distribution Experimental data have shown that idebenone passes the blood-brain barrier and is distributed at significant concentrations in cerebral tissue. Following oral administration pharmacologically relevant concentrations of idebenone are detectable in the aqueous humor of the eye [L885].
Route of elimination The main route of elimination is metabolism, with the majority of dose excreted via the kidneys as metabolites. After a single or repeated oral dose of 750 mg of idebenone, QS4+QS4-C were the most prominent idebenone-derived metabolites in urine, representing on average between 49.3% and 68.3% of the total administered dose. QS6+QS6 represented 6.45% to 9.46%, whereas QS10+QS10-C and IDE+IDE-C were close to 1% or below [L885].
Absorption After oral administration, idebenone is rapidly absorbed. On repeat dosing, maximum plasma concentrations of idebenone are reached on average within 1 hour (median 0.67 h range: 0.33-2.00 h). Food increases the bioavailability of idebenone by approximately 5-7-fold and i therefore should always be administered with food [L885].

N

N06BX13 Idebenone


[N06BX] Other psychostimulants and nootropics


[N06B] PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS


[N06] PSYCHOANALEPTICS


[N] Nervous system

Toxicity Dose Time Species Model Method Action Positive criterion Reference
ELECTRON TRANSPORT CHAIN affect 53
ELECTRON TRANSPORT CHAIN 0.4 μM NADH–Q decrease IC50 106

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 0.4 μM NADH–Q inhibitor IC50 106
quinone antagonist 53

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 1 of 2 companies. For more detailed information, please visit ECHA C&L website


Of the 1 notification(s) provided by 1 of 2 companies with hazard statement code(s):


H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • 2-(12-hydroxydodecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione 6-(12-hydroxydodecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone DB09081
    SCHEMBL7407419 VMHWZDULLBLUMS-UHFFFAOYSA-N ZINC000137375210

    DrugBank Name Idebenone
    DrugBank DB09081
    CAS Number 58186-27-9
    PubChem Compound 3686
    KEGG Compound ID x
    KEGG Drug D01750
    PubChem.Substance 310265009
    ChEBI 31687
    ChemSpider 14944546
    Wikipedia Idebenone
    DPD 20374